![2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00125-019-05039-w/MediaObjects/125_2019_5039_Fig1_HTML.png)
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink
![2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00125-019-05039-w/MediaObjects/125_2019_5039_Fig2_HTML.png)
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink
![The state of diabetes treatment coverage in 55 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 680 102 adults - The Lancet Healthy Longevity The state of diabetes treatment coverage in 55 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 680 102 adults - The Lancet Healthy Longevity](https://www.thelancet.com/cms/asset/b85ee27c-210f-4728-9b4d-d4ecee6a0fce/gr1.jpg)
The state of diabetes treatment coverage in 55 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 680 102 adults - The Lancet Healthy Longevity
66TH ADVANCED POSTGRADUATE COURSE: AGENDA Friday, February 22, 2019 12:30 p.m. – 5:15 p.m. GENERAL SESSION I • Glucose Lower
![Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis - The Lancet Diabetes & Endocrinology Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/asset/b2c0fa87-783e-431b-9875-88b62f1d30c9/gr1.jpg)
Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis - The Lancet Diabetes & Endocrinology
![New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation ... New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation ...](https://www.ahajournals.org/cms/asset/586283c0-4bff-4af8-8d7e-3b0e97d5c2eb/atvbaha.120.315708.fig09.jpg)
New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation ...
![Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary - Endocrine Practice Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary - Endocrine Practice](https://www.endocrinepractice.org/cms/attachment/9cd7b636-d7b6-435a-963b-ab6ece84614a/gr1.jpg)
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary - Endocrine Practice
![New EASD-ADA consensus guidelines on managing hyperglycaemia in type 2 diabetes launched at EASD meeting. New recommendations include specific drug classes for some patients and enhancing medication adherence – Diabetologia New EASD-ADA consensus guidelines on managing hyperglycaemia in type 2 diabetes launched at EASD meeting. New recommendations include specific drug classes for some patients and enhancing medication adherence – Diabetologia](https://diabetologia-journal.org/wp-content/uploads/2018/09/Fig-2-for-EASD-ADA.jpg)
New EASD-ADA consensus guidelines on managing hyperglycaemia in type 2 diabetes launched at EASD meeting. New recommendations include specific drug classes for some patients and enhancing medication adherence – Diabetologia
![Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary - Endocrine Practice Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary - Endocrine Practice](https://www.endocrinepractice.org/cms/attachment/5af1ff48-ac12-4f30-8063-d3f1c658e21c/gr1.jpg)
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary - Endocrine Practice
![Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis | JACC: Heart Failure Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis | JACC: Heart Failure](https://www.jacc.org/cms/asset/af4569b1-651f-4c6c-ae86-6caa19c22d48/fx1.jpg)